NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CTMX

CytomX Therapeutics Inc

Dollar change -0.0875
Percentage change -16.11	%

Apr 04 • 04:00PM ET

0.4556

-0.0875-16.11%

Healthcare • Biotechnology • USA • NASD

Peers: FATE PRTA SRRK IMTX AFMD RCUS RNA ALXO XBIT PVLA

| Held by: VTI VXF FORH IWC

Scroll to Statements

Index	-	P/E	1.16	EPS (ttm)	0.39	Insider Own	2.46%	Shs Outstand	80.10M	Perf Week	-27.48%
Market Cap	36.49M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	-3.90%	Shs Float	78.13M	Perf Month	-26.19%
Income	31.87M	PEG	-	EPS next Q	0.06	Inst Own	58.45%	Short Float	11.53%	Perf Quarter	-57.02%
Sales	138.10M	P/S	0.26	EPS this Y	-97.15%	Inst Trans	-9.78%	Short Ratio	4.92	Perf Half Y	-60.38%
Book/sh	-0.01	P/B	-	EPS next Y	-4527.74%	ROA	19.44%	Short Interest	9.00M	Perf Year	-78.81%
Cash/sh	1.26	P/C	0.36	EPS next 5Y	-	ROE	-	52W Range	0.54 - 5.85	Perf YTD	-55.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	842.20%	52W High	-92.21%	Beta	1.16
Dividend TTM	-	Quick Ratio	1.25	Sales past 5Y	36.21%	Gross Margin	98.72%	52W Low	-16.10%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.25	EPS Y/Y TTM	2446.43%	Oper. Margin	18.10%	RSI (14)	28.87	Volatility	13.70% 10.21%
Employees	121	Debt/Eq	-	Sales Y/Y TTM	36.45%	Profit Margin	23.08%	Recom	1.83	Target Price	4.94
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	1800.81%	Payout	0.00%	Rel Volume	1.12	Prev Close	0.54
Sales Surprise	192.12%	EPS Surprise	212.65%	Sales Q/Q	43.17%	Earnings	Mar 06 AMC	Avg Volume	1.83M	Price	0.46
SMA20	-26.01%	SMA50	-36.10%	SMA200	-56.39%	Trades		Volume	2,041,228	Change	-16.11%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight	$2.25 → $3.50
May-09-24	Upgrade	Wedbush	Neutral → Outperform	$8
May-06-24	Upgrade	Jefferies	Hold → Buy	$2.50 → $8
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$3 → $2.60
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral	$6 → $2
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $1.50
Jul-07-22	Downgrade	Mizuho	Buy → Neutral	$16 → $4
Jul-07-22	Downgrade	Jefferies	Buy → Hold	$12 → $2
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$9
Jan-18-22	Upgrade	Barclays	Underweight → Overweight	$7
Nov-15-21	Initiated	BTIG Research	Buy	$16
May-28-21	Downgrade	Barclays	Equal Weight → Underweight	$9 → $7
Mar-29-21	Initiated	JP Morgan	Overweight	$14
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold	$16 → $10
May-14-20	Reiterated	H.C. Wainwright	Buy	$16 → $12
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight	$7

Show Previous Ratings

Apr-04-25 07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks) -16.11%
Apr-03-25 10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks) -10.78%
Apr-01-25 10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks) -8.78%
Mar-28-25 11:20AM	FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda (Zacks)
Mar-26-25 07:58AM	GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection (Zacks)
02:06AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
Mar-25-25 07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks) -8.17%
Mar-21-25 01:03PM	Elevation Oncology Plunges 42% on Ending Development of Lead Drug (Zacks)
01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
Mar-19-25 01:38PM	SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion (Zacks) +10.93%
Mar-11-25 12:00PM	CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -7.36%
Mar-07-25 06:45PM	CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now (Insider Monkey) +7.71%
07:41AM	Q4 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:35PM	CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:10PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
04:10PM	CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 08:00AM	CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference (GlobeNewswire) -5.76%
07:35AM	Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result (GuruFocus.com)
Feb-27-25 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 12:00PM	All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy (Zacks) -10.53%
Jan-06-25 04:05PM	CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update (GlobeNewswire)
Dec-16-24 09:55AM	CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-27-24 08:00AM	CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 09:35AM	Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround (Zacks)
Nov-08-24 11:54AM	Q3 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.00%
02:32AM	CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 05:55PM	CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:49PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:52AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Nov-06-24 07:52AM	Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result (GuruFocus.com)
Oct-31-24 08:00AM	CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-09-24 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY , in a Phase 1 Study in Patients with Solid Tumors (GlobeNewswire)
Sep-04-24 08:00AM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +11.61%
Aug-10-24 08:18AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-08-24 09:56PM	CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:46PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 08:00AM	CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-25-24 02:26AM	CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-18-24 08:00AM	CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -5.84%
Jun-17-24 04:15PM	CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer (GlobeNewswire)
Jun-05-24 06:00AM	Buy Alert: 3 Penny Stocks That Will Explode in 2024 (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-29-24 06:25AM	No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock. (InvestorPlace)
May-22-24 04:05PM	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 04:15PM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -5.50%
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
May-09-24 04:17PM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript (Insider Monkey) -51.31%
11:56AM	Why Is CytomX (CTMX) Stock Down 43% Today? (InvestorPlace)
11:32AM	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating (MT Newswires)
08:12AM	Q1 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:48AM	Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3 (MT Newswires)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
04:01AM	CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:58PM	CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY T-Cell Engager) (GlobeNewswire)
May-07-24 04:15PM	CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab) (GlobeNewswire) -6.86%
May-06-24 07:09AM	Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8 (MT Newswires)
May-02-24 08:08AM	CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? (Zacks) -12.28%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-01-24 12:11PM	Cannabis Stocks CGC, ACB, TLRY Drop After Huge Rescheduling Rally (InvestorPlace) +214.72%
11:43AM	Why Is CytomX (CTMX) Stock Up 180% Today? (InvestorPlace)
08:00AM	CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire)
Apr-03-24 08:00AM	CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-21-24 08:00AM	CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors (GlobeNewswire)
Mar-18-24 08:00AM	CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-12-24 09:12AM	Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today? (InvestorPlace) -14.34%
08:30AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:46AM	Q4 2023 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-24 05:34PM	CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update (GuruFocus.com)
05:20PM	CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates (Zacks)
04:10PM	CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-24 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 (GlobeNewswire)
Feb-27-24 11:52AM	CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect (Zacks) +36.36%
08:00AM	CytomX Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Jan-24-24 08:00AM	CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b (GlobeNewswire)
Jan-12-24 08:00AM	CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference (GlobeNewswire)
Jan-04-24 08:00AM	CytomX Therapeutics Outlines 2024 Company Priorities and Milestones (GlobeNewswire)
Dec-21-23 08:00AM	CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.22%
Nov-13-23 12:00PM	CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.13%
Nov-08-23 10:15AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:05PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-23 08:00AM	CytomX Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 08:00AM	CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting (GlobeNewswire)
Oct-18-23 04:30PM	CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference (GlobeNewswire)
Sep-05-23 04:05PM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) -5.33%
Aug-25-23 09:35AM	CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-10-23 04:05PM	CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-08-23 05:30PM	CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 08:00AM	CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-20-23 09:00AM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-17-23 08:00AM	CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (GlobeNewswire)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Institutional Ownership

TANG CAPITAL MANAGEMENT LLC	9.34%
BVF INC/IL	6.68%
VANGUARD GROUP INC	6.60%
Prosight Management, LP	4.99%
MILLENNIUM MANAGEMENT LLC	4.12%
ACADIAN ASSET MANAGEMENT LLC	4.01%
Point72 Asset Management, L.P.	3.39%
JACOBS LEVY EQUITY MANAGEMENT, INC	1.98%
Schonfeld Strategic Advisors LLC	1.76%
RENAISSANCE TECHNOLOGIES LLC	1.72%

Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

Period	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period End Date	—	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Period Length	12 Months	12 Months	12 Months	Upgrade your FINVIZ experience Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more. Learn more
Total Revenue	138.10	138.10	101.21
Cost of Goods Sold Incl. D&A	1.77	1.77	2.17
Gross Profit	136.34	136.34	99.04
Selling, General and Administrative Excl. Other	111.34	111.34	105.52
Research and Development	81.76	81.76	75.65
Other Operating Expense	0.00	0.00	0.00
Operating Income	25.00	25.00	-6.48
Interest Expense	0.00	0.00	0.00
Unusual Expense	0.00	0.00	0.00
Net Income Before Taxes	32.09	32.09	3.32
Income Taxes	0.22	0.22	3.89
Consolidated Net Income	31.87	31.87	-0.57
Net Income From Continuing Operations	31.87	31.87	-0.57
Net Income	31.87	31.87	-0.57
EPS (Recurring)	0.40	0.38	-0.01
EPS (Basic, Before Extraordinaries)	0.39	0.38	-0.01
EPS (Diluted)	0.39	0.38	-0.01
EBITDA	26.76	26.76	-4.31
Price To Earnings Ratio	1.16	1.16	6.04
Price To Sales Ratio	0.60	0.63	1.13
Gross Margin	98.72	98.72	97.85
Operating Margin	18.10	18.10	-6.41
Net Margin	23.08	23.08	-0.56
Shares Outstanding	80.10	80.10	67.31
Market Capitalization	36.49	36.49	80.22

Insider Trading Volume

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCarthy Sean A.	CEO	Mar 18 '25	Sale	0.60	37,656	22,556	995,195	Mar 20 04:34 PM
Ogden Christopher	Chief Financial Officer	Mar 18 '25	Sale	0.60	8,551	5,122	201,026	Mar 20 04:33 PM
Chu Yu-Waye	Chief Medical Officer	Mar 18 '25	Sale	0.60	4,025	2,411	135,725	Mar 20 04:32 PM
ROWLAND LLOYD A	General Counsel	Mar 18 '25	Sale	0.60	10,203	6,112	120,594	Mar 20 04:32 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Mar 18 '25	Sale	0.60	19,512	11,688	248,636	Mar 20 04:31 PM
Landau Jeffrey B	Chief Business Officer	Aug 20 '24	Option Exercise	0.00	11,250	0	123,237	Aug 22 06:01 PM
Landau Jeffrey B	Chief Business Officer	Aug 20 '24	Sale	1.23	4,181	5,139	119,056	Aug 22 06:01 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Aug 20 '24	Option Exercise	0.00	11,250	0	179,829	Aug 22 06:01 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Aug 20 '24	Sale	1.23	4,181	5,139	175,648	Aug 22 06:01 PM
ROWLAND LLOYD A	General Counsel	Aug 20 '24	Option Exercise	0.00	11,250	0	134,978	Aug 22 06:00 PM
ROWLAND LLOYD A	General Counsel	Aug 20 '24	Sale	1.23	4,181	5,139	130,797	Aug 22 06:00 PM
Ogden Christopher	Chief Financial Officer	Aug 20 '24	Option Exercise	0.00	6,875	0	110,061	Aug 22 05:59 PM
Ogden Christopher	Chief Financial Officer	Aug 20 '24	Sale	1.23	1,984	2,439	108,077	Aug 22 05:59 PM
McCarthy Sean A.	CEO	Aug 20 '24	Option Exercise	0.00	37,500	0	671,749	Aug 22 05:58 PM
McCarthy Sean A.	CEO	Aug 20 '24	Sale	1.23	13,898	17,082	657,851	Aug 22 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTMX

CytomX Therapeutics Inc

Institutional Ownership

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience